Monday, 15 October 2018
Latest news
Main » Sarepta Therapeutics (SRPT) Receiving Somewhat Favorable Media Coverage, Study Finds

Sarepta Therapeutics (SRPT) Receiving Somewhat Favorable Media Coverage, Study Finds

13 January 2018

Rock Springs Capital Management Lp bought 54,200 shares as the company's stock rose 22.49% with the market. (NASDAQ:SRPT) is performing. Sarepta Therapeutics, Inc. has had 3 insider trades in the last 3 months, including 1 open market buys and 2 sells. The stock increased 5.27% or $2.96 during the last trading session, reaching $59.11.

Sarepta Therapeutics, Inc. (SRPT) reported its last quarterly earnings on 9/29/2017 where the firm reported its Actual EPS of $-0.78/share against the analyst consensus estimate of $-0.85/share. It has outperformed by 80.12% the S&P500.

Jason Karp increased its stake in Sarepta Therapeutics Inc (Call) (SRPT) by 343.69% based on its latest 2017Q3 regulatory filing with the SEC. Mitchell Mcleod Pugh & Williams Inc who had been investing in Apple Inc for a number of months, seems to be less bullish one the $887.69B market cap company. The institutional investor held 27,047 shares of the technology company at the end of 2017Q3, valued at $4.62 million, up from 17,095 at the end of the previous reported quarter. Also, CEO Douglas S. Ingram acquired 38,138 shares of the company's stock in a transaction that occurred on Wednesday, November 8th.

Many analysts are providing their Estimated Earnings analysis for Sarepta Therapeutics, Inc. and for the current quarter 15 analysts have projected that the stock could give an Average Earnings estimate of $-0.32/share. These shares are worth $372,619 and were traded at $55.89 each. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since January 12, 2017 and is uptrending. It has outperformed by 45.78% the S&P500.

Investors sentiment increased to 2.88 in Q3 2017. Its down 0.13, from 1.08 in 2017Q2.

BLACKROCK INC. raised its stake in Sarepta Therapeutics, Inc. Alliancebernstein LP reported 68,500 shares stake. Kingdon Mngmt Llc has 10,000 shares.

Sphera Funds Ltd accumulated 384,997 shares. Moreover, Qs Invsts Ltd Llc has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Susquehanna Grp Inc Llp has invested 0.02% in Sarepta Therapeutics, Inc.

S Muoio & Company, which manages about $129.83 million and $193.79M US Long portfolio, decreased its stake in A/New by 15,000 shares to 179,282 shares, valued at $3.80M in 2017Q3, according to the filing. Lazard Asset Management has 0% invested in Salesforce.com, inc. Smith Asset Group LP holds 9,160 shares. (NASDAQ:SRPT) rating on Tuesday, October 18. Hudson Bay Capital Management Limited Partnership has invested 0.21% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:FB). Jacobs Levy Equity Management holds 0.13% or 40,286 shares. (NASDAQ:SRPT) to report earnings on February, 27. Great West Life Assurance Can invested in 0% or 6,409 shares. Eam Invsts Limited Liability Corp has 61,155 shares for 0.37% of their portfolio. Castleark Management Llc owns 0.4% invested in Sarepta Therapeutics, Inc.

COPYRIGHT VIOLATION NOTICE: "Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Oppenheimer" was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal.

Since October 3, 2017, it had 0 buys, and 1 insider sale for $575,000 activity. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush upgraded it to "Outperform" rating and $56 target in Friday, October 2 report. Moneta Gp Invest Ltd Liability Corp invested 0.09% in Facebook, Inc. On Wednesday, January 4 the stock rating was maintained by Morgan Stanley with "Equal-Weight". The firm has "Outperform" rating by Credit Suisse given on Thursday, September 7. Piper Jaffray maintained Sarepta Therapeutics, Inc. The stock has "Buy" rating by RBC Capital Markets on Wednesday, June 21. The stock has "Buy" rating by Zacks on Monday, August 17. Ruff Shamim had sold 11,500 shares worth $575,000 on Tuesday, October 3. It also reduced its holding in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 150,000 shares in the quarter, leaving it with 450,000 shares, and cut its stake in Acadia Healthcare Company In (NASDAQ:ACHC). During the same quarter in the previous year, the company posted ($0.95) earnings per share. analysts expect that Sarepta Therapeutics will post -3.07 earnings per share for the current fiscal year. CRM's profit will be $79.45M for 248.07 P/E if the $0.11 EPS becomes a reality. Analysts, on average, seem bullish as they suggest EDIT is worth $1.9 more, giving a target price of $33.07 a share. Therefore 67% are positive. Celgene Corporation had 119 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned "Neutral" rating on Monday, April 11 by SunTrust. On Thursday, September 7 the stock rating was maintained by Stifel Nicolaus with "Buy". (NASDAQ:SRPT) earned "Buy" rating by Robert W. Baird on Thursday, August 27. Bernstein initiated it with "Underperform" rating and $10 target in Wednesday, January 11 report. Jefferies has "Buy" rating and $18.0 target.

Since August 8, 2017, it had 0 buys, and 1 insider sale for $53,042 activity. BTIG Research upgraded Celgene Corporation (NASDAQ:CELG) on Thursday, August 4 to "Buy" rating.

Moreover, Dana Advsr Inc has 1.72% invested in Facebook, Inc. Its up 0.02, from 0.68 in 2017Q2. It fall, as 13 investors sold SBCF shares while 29 reduced holdings. 64 funds opened positions while 179 raised stakes. The shares were bought at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Boston Prtn stated it has 197,816 shares or 0.04% of all its holdings. (NASDAQ:SRPT). Kazazian Asset Mngmt Lc holds 5,832 shares. California-based Endurant Limited Partnership has invested 0.92% in Sarepta Therapeutics, Inc.